ReviewPatient preference and adherence2022

Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence.

Sajida Sabsabi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.